Wolverine Trading’s Galectin Therapeutics GALT Stock Holding History

Wolverine Trading’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12,310	Closed	-$23K	–	4839
2022 Q2	$15K	Sell	12,310 -4,049	-25%	-$5.82K	﹤0.01%	4276
2022 Q1	$28K	Buy	+16,359	New	+$31.7K	﹤0.01%	5200
2021 Q2	–	Sell	-16,572	Closed	-$59K	–	6245
2021 Q1	$34K	Buy	+16,572	New	+$37.1K	﹤0.01%	5718
2020 Q3	–	Sell	-13,376	Closed	-$37.5K	–	4734
2020 Q2	$41K	Buy	+13,376	New	+$33.7K	﹤0.01%	4345
2019 Q4	–	Sell	-11,471	Closed	-$39.9K	–	4828
2019 Q3	$42K	Buy	+11,471	New	+$41.5K	﹤0.01%	4083
2019 Q1	–	Sell	-21,139	Closed	-$101K	–	4776
2018 Q4	$80K	Buy	21,139 +4,012	+23%	+$19.2K	﹤0.01%	4051
2018 Q3	$103K	Buy	+17,127	New	+$94.2K	﹤0.01%	4533
2017 Q4	–	Sell	-17,407	Closed	-$37K	–	5101
2017 Q3	$37K	Sell	17,407 -7,559	-30%	-$15K	﹤0.01%	4269
2017 Q2	$59K	Buy	+24,966	New	+$66.5K	﹤0.01%	4026
2016 Q4	–	Sell	-29,056	Closed	-$35K	–	4657
2016 Q3	$35K	Buy	+29,056	New	+$51.7K	﹤0.01%	4453

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Wolverine Trading's GALT Position: Q3 2022 in Review

Wolverine Trading sold out of Galectin Therapeutics (GALT) in Q3 2022, closing a stake of 12,310 shares — an estimated $23K sold.

Wolverine Trading first reported a position in GALT in Q3 2016 and held it in 10 quarters. The position peaked at $103K in Q3 2018. 59 funds tracked by Wall St. Rank hold GALT as of Q3 2022.

Wolverine Trading reported no remaining Galectin Therapeutics position as of Q3 2022 after selling out during the quarter.
Wolverine Trading sold 12,310 Galectin Therapeutics shares in Q3 2022, an estimated $23K.
Wolverine Trading first reported a position in Galectin Therapeutics in Q3 2016 and held it in 10 quarters.
Wolverine Trading's Galectin Therapeutics position peaked at $103K in Q3 2018.
59 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2022.

Based on Wolverine Trading's 13F filing for Q3 2022, filed 14 Nov 2022.